

detecting a signal from said immunoassay resulting from said antibody binding said free and complexed cardiac specific troponin T, wherein said signal is related to the presence or amount of said free and complexed cardiac specific troponin T in said sample.

130. An assay according to claim 129, wherein said patient sample is selected from the group consisting of a blood sample, a serum sample, and a plasma sample.

131. An assay according to claim 129, wherein said signal is approximately equal for equal amounts of said free cardiac specific troponin T and said complexed cardiac specific troponin T.

132. An assay according to claim 129, wherein said detectable signal is within a factor of 0.2 for equal amounts of said free cardiac specific troponin T and said complexed cardiac specific troponin T.

133. An assay according to claim 129, wherein said detectable signal is within a factor of 2 for equal amounts of said free cardiac specific troponin T and said complexed cardiac specific troponin T.

Remarks

Applicants submit this preliminary amendment with an accompanying divisional patent application filed under 37 C.F.R. §1.53(b). The accompanying patent application is a divisional of co-pending U.S. Application Serial No. 08/633,248 filed April 18, 1996. The accompanying application is a true copy of U.S. Patent Application Serial No. 08/633,248.

The instant claims are fully supported by the specification and do not introduce new matter. The instant claims embody the subject matter of claims 101-148 of U.S. Application Serial No. 08/633,248, which were subject to a restriction requirement in an Office Action mailed on August 5, 1998.

Additionally, support for measurement of cardiac specific isoforms of troponin in patient samples, and particularly blood, serum, and plasma samples, can be found in the specification on page 10, lines 5-21.

Conclusion

Applicants respectfully submit that the foregoing claims are in condition for allowance. An early notice to that effect is earnestly solicited. Should any matters remain outstanding, the Examiner is encouraged to telephone the undersigned at (619) 552-8400 so that they may be resolved without the need for additional action and response thereto.

Respectfully submitted,

LYON & LYON

Dated 07/07/99By 

For Richard J. Warburg,
Daniel M. Chambers
Registration No. 34,561

First Interstate World Center
633 West Fifth Street, 47th Floor
Los Angeles, CA 90071-2066
(213) 489-1600